Vincent Eric Xu

Dr. Vincent Eric Xu

Medicine, University of Wisconsin Hospital and Clinics, Madison, Alabama, USA
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
RARyan Michael Antar
Ryan Michael Antar
CFChristopher Chucri Fawaz
Christopher Chucri Fawaz
DGDIEGO GONZALEZ
DIEGO GONZALEZ
VXVincent Eric Xu
Vincent Eric Xu
ADArthur Drouaud
Arthur Drouaud
MWMichael Whalen
Michael Whalen
The genetic landscape of urologic cancers has evolved with the identification of actionable mutations that impact diagnosis, prognosis, and therapeutic strategies. This narrative review consolidates existing literature on genetic mutations across key urologic cancers, including bladder, renal, prostate, upper tract urothelial, testicular, and penile. The review highlights mutations in DNA damage repair genes, such as BRCA1/2 and PTEN, as well as pathway alterations like FGFR and PD-L1 overexpression. These mutations influence tumor behavior and therapeutic outcomes, emphasizing the need for precision oncology approaches. Molecular profiling, through tools like next-generation sequencing, has revolutionized patient care by enabling targeted treatment strategies, especially in cancers with distinct molecular subtypes such as luminal or basal bladder cancer and clear cell renal carcinoma. Emerging therapies, including FGFR inhibitors and immune checkpoint blockade, offer new treatment avenues, although resistance mechanisms remain a challenge. We also emphasize the importance of biomarker identification for personalized management, especially in metastatic settings where treatment intensification is often required. Future research is needed to further elucidate our understanding of the genetics affecting urologic cancers, which will help develop novel, individualized therapies to enhance oncologic outcomes.

2 May 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
RARyan M. Antar
Ryan M. Antar
VXVincent Eric Xu
Vincent Eric Xu
OAOluwafolajimi Adesanya
Oluwafolajimi Adesanya
ADArthur Drouaud
Arthur Drouaud
NLNoah Longton
Noah Longton
MWMichael Whalen
Michael Whalen
Background: Muscle-invasive bladder cancer (MIBC) is a potentially fatal disease, especially in the setting of locally advanced or node-positive disease. Adverse outcomes have also primarily been associated with low-income status, as has been reported in other cancers. While the adoption of neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy (RC) and pelvic lymph node dissection (PLND) has improved outcomes, these standard-of-care treatments may be underutilized in lower-income patients. We sought to investigate the economic disparities in NAC and PLND receipt and survival outcomes in MIBC. Methods: Utilizing the National Cancer Database, a retrospective cohort analysis of cT2-4N0-3M0 BCa patients with urothelial histology who underwent RC was conducted. The impact of income level on overall survival (OS) and the likelihood of receiving NAC and PLND was evaluated. Results: A total of 25,823 patients were included. This study found that lower-income patients were less likely to receive NAC and adequate PLND (≥15 LNs). Moreover, lower-income patients exhibited worse OS (Median OS 55.9 months vs. 68.2 months, p < 0.001). Our findings also demonstrated that higher income, treatment at academic facilities, and recent years of diagnosis were associated with an increased likelihood of receiving standard-of-care modalities and improved survival. Conclusions: Even after controlling for clinicodemographic variables, income independently influenced the receipt of standard MIBC treatments and survival. Our findings identify an opportunity to improve the quality of care for lower-income MIBC patients through concerted efforts to regionalize multi-modal urologic oncology care.

27 July 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
ADArthur Drouaud
Arthur Drouaud
VXVincent Eric Xu
Vincent Eric Xu
AVAlejandro Velasquez
Alejandro Velasquez
RARyan Antar
Ryan Antar
BBBrandon Boyarsky
Brandon Boyarsky
MWMichael Whalen
Michael Whalen

17 September 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
VXVincent Eric Xu
Vincent Eric Xu
OAOluwafolajimi Adesanya
Oluwafolajimi Adesanya
SASarah Azari
Sarah Azari
SISamita Islam
Samita Islam
MKMatthew Klein
Matthew Klein
MWMichael Whalen
Michael Whalen

12 March 2024 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
VXVincent Eric Xu
Vincent Eric Xu
RARyan M Antar
Ryan M Antar
LBLuca Bertozzi
Luca Bertozzi
ADArthur Drouaud
Arthur Drouaud
SASarah Azari
Sarah Azari
MWMichael Whalen
Michael Whalen

10 February 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
MKMatthew N. Klein
Matthew N. Klein
OAOluwafolajimi Adesanya
Oluwafolajimi Adesanya
VXVincent Eric Xu
Vincent Eric Xu
OGOlivia Gordon
Olivia Gordon
RARyan M. Antar
Ryan M. Antar
MWMichael Whalen
Michael Whalen